



Australian Government
Australian Pesticides and
Veterinary Medicines Authority



REPORT OF ADVERSE EXPERIENCES

for Veterinary Medicines and Agricultural Chemicals

Calendar Year 2008

SEPTEMBER 2009

© Commonwealth of Australia 2009

This work is copyright. Apart from any use permitted under the *Copyright Act 1968*, no part may be reproduced without permission from the Australian Pesticides & Veterinary Medicines Authority. Requests and inquiries concerning reproduction and rights can be made to:

The Manager, Public Affairs
Australian Pesticides and Veterinary Medicines Authority
PO Box 6182
KINGSTON ACT 2604
Australia

Email: communications@apvma.gov.au

This document is published by the APVMA. In referencing this document the APVMA should be cited as both author and publisher.

ISBN: [Enter ISBN Number if required (consult with Information Services) or delete if not required]

Website: This publication is available from the APVMA website: <http://www.apvma.gov.au>

Comments and enquiries may be directed to:

Adverse Experience Reporting Manager
Australian Pesticides & Veterinary Medicines Authority
PO Box 6182
KINGSTON ACT 2604
Australia

Telephone: +61 2 6210 4806

Fax: +61 2 6210 4812

Email: [Enter Email address if appropriate or delete if not required]

EXECUTIVE SUMMARY	1
1 INTRODUCTION	3
1.1 Program outline	3
1.2 What is an adverse experience?	3
1.3 Who can report an adverse experience?	4
1.4 How to report an adverse experience?	5
1.5 Benefits of the AERP	5
1.6 Evaluation of adverse experience reports	5
1.7 Classification of adverse experience reports	6
1.8 Corrective action determination	7
1.9 Outcomes of the program	7
1.10 Report Structure	8
1.11 For further information	9
2 VETERINARY - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (ANIMAL)	10
2.1 Adverse experience report summaries for each species listed by active constituent	10
3 VETERINARY - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (HUMAN)	123
3.1 Adverse experience report summaries involving humans listed by active constituent	123
4 AGRICULTURE - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (STANDARD)	131
4.1 Adverse experience report summaries involving crop damage, domestic animal harm, environmental damage or lack of efficacy listed by active constituent	131
5 AGRICULTURE - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (HUMAN)	134
5.1 Adverse experience report summaries involving humans listed by active constituent	134
GLOSSARY	137
LIST OF ACTIVE CONSTITUENTS	139

EXECUTIVE SUMMARY

The Adverse Experience Reporting Program for veterinary medicines (AERP Vet) and the AERP for agricultural chemicals (AERP Ag) are quality assurance programs that facilitate the management of veterinary medicines and agricultural chemicals throughout their lifecycle, from registration to end product user.

This report contains information on adverse experience reports for veterinary medicines (Chapter 2 and 3) and agricultural chemicals (Chapter 4 and 5). This report is also available online from the APVMA website at www.apvma.gov.au.

AERP Vet - During the 2008 calendar year a total of 1712 adverse experience reports were classified by the APVMA. Of these, 1079 were classified as '*probable*' or '*possible*'. These included 839 *standard* animal reports and 9 *human* reports and 231 reports relating to '*lack of efficacy*'. The adverse experience reports in animals were submitted by veterinary surgeons, pet owners, farmers, members of the public and product registrants.

AERP Ag - During the 2008 calendar year a total of 123 adverse experience reports were classified by the APVMA. Of these, 24 reports were classified as '*probable*' or '*possible*'. These included 2 *human* reports, 15 *environmental* reports and 4 *standard* crop or animal ..reports. There were 3 reports relating to '*lack of efficacy*'. In addition, numerous enquiries about Agvet chemicals were received from members of the public.

The quality of the information provided in the reports was generally of a high standard, which in part reflects the good interaction between the APVMA, the veterinary profession, the agricultural community and registrants.

Off-label incidents are not included in this report. However, it is valuable to report off-label adverse experiences as these can cover very serious incidents. For example:

- Poor anaesthetic treatment protocols have resulted in delayed recovery or death of animals, with some instances of treatment protocols clearly contradicting the label.
- Concurrent use of medications, particularly non-steroidal anti-inflammatory drugs, continues to result in a variety of veterinary adverse experience reports.
- The use of dog products on cats has caused serious injury to cats. This action is clearly off-label and the public should be aware that some ingredients are toxic to cats and that dose rates are significantly different between the two species.
- There were a total of 104 human reports received in 2008 across AERP Ag and Vet. The reports were classified as follows : 11 '*probable or possible*', 60 '*off-label*', and 33 '*unlikely or unknown*'. 57 percent were related to off-label product use, including needle stick injuries, which continue to cause concern. Individuals involved in animal husbandry should take appropriate preventative action when injecting animals.

Throughout 2008 a number of risk management strategies aimed at mitigating and minimising the number of adverse events were actioned.

These included:

- Proactive management of issues associated with permethrin toxicity in cats

Other activities undertaken by the AERP during 2008 included:

- Encouraging reporting through networks of the members of APVMA's Community Consultative Committee (CCC)
- Raising awareness of the AERP program in the wider community through presentations and advertising.
- Promoting AERP and displaying the AERP banner at the Australian Veterinary Association (AVA) Conference in Perth in May 2008.
- Publishing an AERP article and advertising the AERP banner in the Farm Guide Magazine 2008.

1 INTRODUCTION

1.1 Program outline

The APVMA is the Australian government authority which manages the National Registration Scheme for Agricultural and Veterinary Chemicals. It is responsible for the assessment, evaluation and registration (marketing authorisation) of pesticides and veterinary medicines prior to sale, and their regulation up to and including the point of retail sale. The APVMA also manages quality assurance programs that monitor the safety and performance of registered products.

'Veterinary Medicines' include all veterinary chemical products such as vaccines, antibiotics, parasiticides for worms, lice, fleas and ticks, anti-inflammatory and anti-arthritic agents, nutritional supplements, therapeutic pet foods and diets for both companion and production animals.

'Pesticides' and 'Agricultural Chemicals' include agricultural and household chemicals such as insecticides, herbicides and fungicides, water treatment products including swimming pool products, products for treating algae and mould and products for preventing rot and infestation in marine structures.

The Adverse Experience Reporting Program (AERP) is a post-registration quality assurance program established by the APVMA to help facilitate the management of veterinary medicines and agricultural chemicals throughout their lifecycle. The program provides a means of identifying corrective action that may be necessary to assure the continued safety, quality and effectiveness of registered products. Recording and investigating reports of adverse experiences is an important step in detecting unusual or rare conditions that were not evident in clinical or field trials and, as a result, could not be assessed during the product registration process. The AERP helps to ensure that products on the market:

- remain safe, effective and of acceptable quality
- are used in the best possible way
- include instructions and warnings on the label that are appropriate.

1.2 What is an adverse experience?

The APVMA defines an **AERP Vet adverse experience** as:

An unintended or unexpected (deleterious) effect on animals, human beings or the environment, including injury, sensitivity reactions or lack of efficacy associated with the clinical use of a veterinary chemical product when used according to label instructions.

A number of veterinary medicines have known side effects when used as directed and it is useful to maintain a record of these to be able to assess their true incidence. Furthermore, because of the enormous diversity amongst animal species and the relatively small number of veterinary medicines in the marketplace, it is occasionally necessary to use products in circumstances where there is limited information available on the dose rates or adverse reactions in off-label species. Such products may have originally been intended for

use in humans or other animal species. For this reason it is important that all adverse experiences, whether associated with recommended label use or not, are reported.

The APVMA defines an **AERP Ag adverse experience** as:

An unintended or unexpected effect (deleterious) on plants, plant products, animals, human beings or the environment, including injury, sensitivity reactions or lack of efficacy associated with the use of an agricultural chemical product when used according to label directions.

It is possible that some agricultural chemicals may cause effects when used according to the label and it is useful to maintain a record so that the true incidence of any unwanted effects can be assessed. Thus it is important to report all adverse experiences.

Adverse Experiences - Serious and Minor

The APVMA defines a **serious adverse experience** as one that involves:

- widespread and significant crop and plant damage (eg. crop death, severe stunting or significant yield loss)
- life-threatening or other significant effects in a human, including death
- farm, domestic and native animal deaths or
- significant environmental damage, including fish kills and water quality issues.

The APVMA defines a **minor adverse experience** as one that involves:

- crop and plant damage that is not widespread or significant (e.g. minor wilting or yellowing of crops, minor yield loss)
- human health effects that require medical attention, but are not life-threatening
- injury to domestic and native animals that require veterinary attention or
- minor environmental damage.

1.3 Who can report an adverse experience?

Anyone can submit an adverse experience report for a Veterinary Medicine or Agricultural Chemical. The APVMA encourages voluntary reporting, particularly from veterinarians, animal owners, farmers, gardeners, agronomists, health workers, bystanders, state and territory authorities and other users of veterinary medicines and agricultural chemicals.

Registrants of veterinary medicines and agricultural chemicals also have a legal obligation to report to the AERP. Under Section 161 of the *Agvet Code*, registrants must provide the APVMA with any new information that comes to their attention. This new information may include adverse experience information on human health issues, harm to animals, damage to plants, property or the environment, or lack of efficacy when the

products are used according to label directions. The registrant reporting component of AERP Ag is one method by which registrants can meet certain legislative obligations of Section 161 of the *Agvet Code*.

1.4 How to report an adverse experience?

Adverse experiences can be reported online at <https://services.apvma.gov.au/AerpWebApp/> or by using the Adverse Experience Reporting Form, or by contacting the AERP directly (contact details are on page 9).

1.5 Benefits of the AERP

The AER Program provides numerous benefits to a wide range of stakeholders.

Benefits to the community

- helps ensure the safety and efficacy of registered products in the marketplace
- provides confidence in the regulatory system.
- provides up-to-date safety information on registered products
- ensures that the latest safety information is available on product labels
- provides information on modifications needed to work practices to ensure safe use of chemicals
- identifies and acts on emerging issues quickly.

Benefits to States and Territories

- provides a format for communication of issues that cross over jurisdictional boundaries.

1.6 Evaluation of adverse experience reports

Reports received by the APVMA are assessed to determine whether the adverse experience is related to the use of, or exposure to, the product.

Procedures for dealing with adverse experience reports are as follows:

- Reports made directly to the APVMA (voluntary reports) are copied to the product registrant for investigation. The registrant may then contact either the reporting person or the attending veterinarian and discuss the matter to determine if any follow up laboratory, pathology or other veterinary work is required.
- The product registrant subsequently provides the APVMA with an investigation report into the incident. The APVMA assesses this information and determines whether any further investigative work is required. In some cases, additional expert opinion may be sought from relevant State or Territory government agencies like the Office of Chemical Safety and Environmental Health (OCSEH), the Department of the Environment, Water, Heritage and the Arts (DEWHA), universities, the Australian Veterinary Association, or other appropriate authorities.

- The APVMA will also consider published scientific information or information provided by an equivalent international organisation.
- In all cases a standard method of assessment is used to determine whether the adverse experience may have been related to the use of the veterinary medicine or agricultural chemical (i.e. 'classification'; see 1.7 below). The APVMA also considers whether the product was used according to the label directions.
- The person submitting making the report will be advised of the outcome of the investigations.
- If a report of an adverse experience is made directly to the product registrant, they will provide a report to the APVMA (Registrant report). The APVMA will then assess this information and determine whether any further investigative or regulatory action is required.

1.7 Classification of adverse experience reports

The relationship between the use of a product and the reported clinical signs is determined after the incident has been investigated. This relationship is expressed in terms of ***probable, possible, probable or possible off-label, unlikely and unknown***.

Probable

For inclusion in the category *probable*, all of the following minimum criteria should be met:

- there should be a reasonable association between the administration of the product and onset and duration of the reported adverse experience,
- the description of the clinical signs should be consistent with or at least plausible given the known pharmacology and toxicology of the product, and
- there should be no other equally plausible explanation (or contributing factors) for the clinical signs.

When any of the above criteria cannot be satisfied (due to lack of sufficient information or conflicting data) then the association cannot be assessed as *probable*.

Possible

For inclusion in the category *possible*, association of the adverse experience with administration of the primary suspect product is one of other possible and equally plausible explanations (or contributing factors) for the described adverse experience.

Probable or Possible Off-label

This is as per the classification of *probable* or *possible* but where there is obvious evidence of off-label use (including use in species not listed on the product label, over-dosing or under-dosing). It is acknowledged that depending on State and Territory legislation and veterinary prescribing privileges, APVMA permits and other legal exemptions may allow off-label use in some situations.

Unlikely

Where sufficient information exists to establish that the described adverse experience was not likely to have been associated with administration or use of the product(s), or other more plausible explanations exist, the assessment should be categorised as *unlikely*.

Unknown

All adverse experiences for which reliable data are either unavailable or are insufficient to make an assessment should be categorised as *unknown*.

1.8 Corrective action determination

The APVMA takes into account a broad range of issues and options when deciding what, if any, corrective action is required to mitigate possible risks to humans, animals, or the environment.

For each registered veterinary medicine, and more broadly for each active constituent, the APVMA conducts a trend analysis of all adverse experience reports received. All reports that have been classified as probable or possible are compared to the total number of doses sold within the relevant financial year and a 'reporting incidence' is calculated (i.e. the number of adverse experience reports per number of doses sold). A control limit or 'warning line' for reporting incidence figures, which indicate that further action may be required is one or more per 10,000 doses sold¹. This report also recommends that if the reporting incidence is greater than one per 10,000 in two out of three consecutive years or an exceptional incidence of three or more per 10,000 occurs on any one occasion, or a consistent rising trend is seen over five years (irrespective of the reporting incidence), then action may be taken.

The APVMA considers other scientific literature and information relating to trend analysis and risk assessment when determining whether corrective action is required. The APVMA also takes into account whether the noted clinical signs are listed in warning statements on the product label, in which case a slightly higher reporting incidence may be acceptable, and also considers the severity of clinical signs (i.e. more severe signs may trigger corrective action at a lower reporting incidence).

1.9 Outcomes of the program

Based on the assessment of adverse experience reports certain risk mitigation strategies or corrective actions may be requested. These may include, but are not restricted to, the following:

- registration amendments, such as label changes, changes to the method of manufacture or the product's physical or chemical design, changes to container design, changes to production line processes, or suspension and/or cancellation of registration and approval

¹ *Final Report to the Veterinary Products Committee*. Department for Environment, Food & Rural Affairs, United Kingdom, 2002.

- review of the active constituent under the APVMA's Chemical Review Program
- referral for action, such as compliance action, including product and batch recalls, referral to state authorities for action, or nomination of products or active constituents for formal chemical review by the APVMA, (note that once the recommendation for review has been made by the AERP the review program will conduct consultation and scoping prior to determining whether a review is necessary or not)
- education and publicity, such as providing scientific papers or articles on issues identified for relevant journals, magazines or newspapers. When required education can be directed toward veterinary profession, farming community or wider public on issues relating to use of products.

The conclusions drawn by the APVMA during the investigation and evaluation of each adverse experience report will be provided to the reporting person. This will include an explanation of whether the APVMA considers that the observed adverse effects (including health symptoms) were related to the use of or exposure to the product. The APVMA will explain what these conclusions are and what corrective action, if any, needs to be taken in response to the information.

The information contained in this report is only a general reference to the type of adverse experiences that have been reported either to the APVMA or to product registrants. This report does not provide any correlation between the number of units of each product sold and the number of adverse experiences for each product reported. It must also be noted that each product may have more than one active constituent and hence the adverse experience reported may be related to any one or more of the active constituents present in the particular product reported to the AERP.

Therefore this information should not be used for:

- associating adverse effects with a particular product or active constituent
- assessing the safety and efficacy of a product or active constituent
- establishing acceptable frequency of occurrence of an adverse experience, or
- comparing one product or active constituent with another product or active constituent.

1.10 Report Structure

This report is arranged into the following sections:

Chapters 2 and 3 AERP *Vet*

- Chapter 2 is a summary of adverse experience reports other than human health (including farm, domestic and native animals, environmental damage and lack of efficacy) listed by active constituent.
- Chapter 3 is a summary of adverse experience reports involving human health.

Chapters 4 and 5 AERP *Ag*

- Chapter 4 is a summary of adverse experience reports other than human health (including crop damage, environmental damage and lack of efficacy) listed by active constituent.
- Chapter 5 is a summary of adverse experience reports involving human health.

The reports presented in the Tables below are for each '**active constituent**' and are classified as '**probable**' and '**possible**'. The information for each active is divided into '**species affected**'. Several species tables may be present for each active constituent. For effects on humans the reports are presented in Tables 3.2 and 5.2. Multiple '**presenting signs**' may be present for any one report, these are listed under '**incidence**' in the second table.

ACTIVE CONSTITUENT

Species Affected

NUMBER OF REPORTS	PROBABLE	POSSIBLE
X+Y	X	Y

PRESENTING SIGN	INCIDENCE
Burn(s)	A
Scabs	B
Skin slough	C

1.11 For further information

For information about the Adverse Experience Reporting Program please contact:

Dr Elvira Currie

Phone: +61 2 6210 4806

Fax: +61 2 6210 4813

Email: elvira.currie@apvma.gov.au or AERPcoordinator@apvma.gov.au

2 VETERINARY - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (ANIMAL)

2.1 Adverse experience report summaries for each species listed by active constituent

Active constituent name

- Each active constituent is listed alphabetically, with a summary of the adverse experience reports.
- It is important to note that the number of adverse experience reports and the presenting signs observed may be listed under more than one active constituent if they refer to a product that contains multiple active constituents.

The species

- For each active constituent, the adverse experience reports are listed by species in alphabetical order.

Number of reports

- Only adverse experience reports that were classified by the APVMA during the calendar year 2008 as being either probable or possible have been included in these lists. The summary table indicates how many reports were classified as probable and how many were classified as possible.

Presenting signs

- All observed clinical signs for reports that were classified as probable and possible are listed in order of frequency.
- It is important to note that multiple clinical signs have been noted in some individual reports. Therefore the list of clinical signs observed does not relate directly to the total number of reports received.

Summary of corrective action

- No regulatory action was required for many of the active constituents as the frequency of adverse experience reports received was relatively low when compared with the total number of doses sold. A short narrative is provided on any corrective action taken as a result of assessment of the adverse experience information for an active constituent.
- In many instances, the potential for adverse reactions to many veterinary medicines was recognised at the time of product registration. When adverse experiences are reported for such medicines, the need for corrective action is considered against the data assessed at the time of product registration.

2.2 Veterinary - standard AERs

ABAMECTIN

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

ACEPROMAZINE MALEATE

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1
Respiratory problems	1
Sedation (prolonged)	1

ALBENDAZOLE*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	1	2

PRESENTING SIGN	INCIDENCE
Lack of effect	3

ALPHA AMYLASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

ALPHA-CYPERMETHRIN*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	1	2

PRESENTING SIGN	INCIDENCE
Lack of effect	3

ALPHAXALONE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	2	2

PRESENTING SIGN	INCIDENCE
Apnoea	1
Cyanosis	2
Diarrhoea	1
Recovery (poor)	1
Seizure	1
Vomiting	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
11	2	9

PRESENTING SIGN	INCIDENCE
Death	2
Swelling (local)	2
Swollen (ears)	2
Swollen feet	2
Apnoea	1
Ataxia	1
Behavioural change	1
Cardiac arrest	1
Coughing	1
Cyanosis	1
Erythema	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1
Lame	1
Opisthotonos	1
Pain	1
Respiratory problems	1
Seizure	1

ALUMINIUM HYDROXIDE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
22	7	15

PRESENTING SIGN	INCIDENCE
Abscess	2
Injection site reaction	14
Lump (local)	8
Pain	4
Pyrexia	3
Lethargy	2
Anorexia	1
Collapse	1
Depression	1
Epistaxis	1
Facial oedema	1
Immune-mediated haemolytic anaemia	1
Leucopenia	1
Muscle stiffness	1

PRESENTING SIGN	INCIDENCE
Oedema	1
Polyarthritis	1
Site reaction	1
Thrombocytopenia	1
Vomiting	1

AMITRAZ*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Bloat	1
Death	1
Lethargy	1

AMOXYCILLIN AS AMOXYCILLIN TRIHYDRATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Injection site reaction	2
Abscess	1
Lump (local)	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1

ANAPLASMA CENTRALE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
10	0	10

PRESENTING SIGN	INCIDENCE
Lack of effect	8
Death	2
Vaccination reaction	1

BABESIA BIGEMINA*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
10	0	10

PRESENTING SIGN	INCIDENCE
Lack of effect	8
Death	2
Vaccination reaction	1

BABESIA BOVIS*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
10	0	10

PRESENTING SIGN	INCIDENCE
Lack of effect	8
Death	2
Vaccination reaction	1

BENAZEPRIL HYDROCHLORIDE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lethargy	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Vomiting	1

BENZATHINE PENICILLIN*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	1	1

PRESENTING SIGN	INCIDENCE
Death	2
Ataxia	1
Stiffness	1

BETA GLUCANASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

BETAMETHASONE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	0	3

PRESENTING SIGN	INCIDENCE
Deafness	3

BORDETELLA BRONCHISEPTICA*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
28	2	26

PRESENTING SIGN	INCIDENCE
Coughing	12
Vomiting	7
Anorexia	5
Lethargy	4
Depression	2
Pain	2
Periorbital swelling	2
Pyrexia	2
Sneezing	2
Vocalisation	2
Agitation	1
Alopecia (localised)	1
Anaphylaxis	1
Facial oedema	1
Frothing at the mouth	1
Haemorrhagic gastroenteritis	1
Injection site reaction	1
Lump (local)	1
Malaise	1
Nasal discharge	1
Respiratory problems	1
Tremor	1

PRESENTING SIGN	INCIDENCE
Urticaria	1

BORDETELLA BRONCHISEPTICA (INACTIVATED CELL FREE EXTRACT)*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
108	62	46

PRESENTING SIGN	INCIDENCE
Lethargy	46
Pain	36
Vomiting	22
Injection site reaction	21
Anorexia	19
Facial oedema	19
Shaking	12
Pyrexia	9
Lump (local)	8
Urticaria	8
Collapse	4
Depression	4
Erythema	4
Pale mucous membranes	4
Pruritis	4
Swollen lips and face	3
Abscess	2
Ataxia	2
Disorientation	2

PRESENTING SIGN	INCIDENCE
Restless	2
Site reaction	2
Thrombocytopenia	2
Weakness	2
Wheals	2
Anaphylactoid reaction	1
Anaphylaxis	1
Bradycardia	1
Coughing	1
Diarrhoea	1
Distress	1
Dyspnoea	1
Epistaxis	1
Hives	1
Hypersalivation	1
Hypotension	1
Immune-mediated haemolytic anaemia	1
Incontinence	1
Leucopenia	1
Malaise	1
Muscle stiffness	1
Oedema	1
Polyarthritis	1
Pupillary light reflex (abnormal)	1
Site reaction (swelling)	1
Tachypnoea	1
Unconscious	1

PRESENTING SIGN	INCIDENCE
Urination	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

BORDETELLA BRONCHISEPTICA KILLED VACCINE

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	0	6

PRESENTING SIGN	INCIDENCE
Allergy	3
Diarrhoea	3
Facial oedema	3
Vomiting	3

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

BORIC ACID

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	0	6

PRESENTING SIGN	INCIDENCE
Irritation (skin)	1

CALCIUM PENTOSAN POLYSULFATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Collapse	1
Death	1

CAMPYLOBACTER FELIS (VIBRO FETUS) VENEREALIS BIOTYPE 1*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Injection site reaction	2
Anorexia	1
Oedema	1

CANINE ADENOVIRUS TYPE 2*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
100	54	46

PRESENTING SIGN	INCIDENCE
Lethargy	44
Pain	31
Vomiting	26
Facial oedema	21

PRESENTING SIGN	INCIDENCE
Anorexia	19
Shaking	14
Injection site reaction	8
Urticaria	8
Pyrexia	7
Coughing	4
Depression	4
Diarrhoea	4
Erythema	4
Pale mucous membranes	4
Pruritis	4
Allergy	3
Collapse	3
Swollen lips and face	3
Weakness	3
Anaphylaxis	2
Ataxia	2
Disorientation	2
Frothing at the mouth	2
Restless	2
Tremor	2
Wheals	2
Bradycardia	1
Distress	1
Dyspnoea	1
Haemorrhagic gastroenteritis	1
Hives	1

PRESENTING SIGN	INCIDENCE
Hypersalivation	1
Hypotension	1
Lack of effect	1
Lump (local)	1
Malaise	1
Paresis	1
Pupillary light reflex (abnormal)	1
Site reaction	1
Site reaction (swelling)	1
Sneezing	1
Tachypnoea	1
Thrombocytopenia	1
Unconscious	1
Urination	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CANINE ADENO VIRUS TYPE 2 – LIVE (INFECTIOUS HEPATITIS)*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
16	5	11

PRESENTING SIGN	INCIDENCE
Injection site reaction	8
Lump (local)	6
Lethargy	3
Pain	3
Anorexia	2
Collapse	1
Epistaxis	1
Facial oedema	1
Immune-mediated haemolytic anaemia	1
Polyarthritis	1
Pyrexia	1
Thrombocytopenia	1

CANINE ADENOVIRUS TYPE 2 LIVE (CAV II)*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	1	3

PRESENTING SIGN	INCIDENCE
Anaphylactoid reaction	1
Injection site reaction	1
Lethargy	2
Vomiting	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CANINE ADENOVIRUS TYPE 2 STRAIN MANHATTAN - LIVE

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
14	2	12

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Vomiting	5
Pain	3
Pyrexia	3
Abscess	2
Anorexia	2
Depression	2
Lump (local)	2
Periorbital swelling	2
Vocalisation	2
Agitation	1
Alopecia (localised)	1
Lethargy	1
Leucopenia	1
Malaise	1
Muscle stiffness	1
Oedema	1
Site reaction	1

PRESENTING SIGN	INCIDENCE
Tremor	1
Urticaria	1

CANINE DISTEMPER*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

CANINE DISTEMPER VIRUS*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
19	2	17

PRESENTING SIGN	INCIDENCE
Lethargy	6
Vomiting	6
Facial oedema	4
Pyrexia	4
Allergy	3
Anorexia	3
Diarrhoea	3
Restless	2
Anaphylaxis	1
Ataxia	1
Coughing	1

PRESENTING SIGN	INCIDENCE
Depression	1
Frothing at the mouth	1
Haemorrhagic gastroenteritis	1
Injection site reaction	1
Lack of effect	1
Lump (local)	1
Pain	1
Paresis	1
Pupillary light reflex (abnormal)	1
Weakness	1

CANINE DISTEMPER VIRUS - LIVING*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
99	58	41

PRESENTING SIGN	INCIDENCE
Lethargy	43
Pain	33
Vomiting	21
Anorexia	18
Facial oedema	18
Injection site reaction	16
Shaking	14
Urticaria	8
Lump (local)	6
Collapse	4

PRESENTING SIGN	INCIDENCE
Erythema	4
Pale mucous membranes	4
Pruritis	4
Pyrexia	4
Depression	3
Swollen lips and face	3
Disorientation	2
Thrombocytopenia	2
Tremor	2
Weakness	2
Wheals	2
Anaphylactoid reaction	1
Anaphylaxis	1
Ataxia	1
Bradycardia	1
Coughing	1
Diarrhoea	1
Distress	1
Dyspnoea	1
Epistaxis	1
Hives	1
Hypersalivation	1
Hypotension	1
Immune-mediated haemolytic anaemia	1
Malaise	1
Polyarthritis	1
Site reaction	1

PRESENTING SIGN	INCIDENCE
Site reaction (swelling)	1
Tachypnoea	1
Unconscious	1
Urination	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CANINE DISTEMPER VIRUS STRAIN ONDERSTEPSPOORT

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
14	2	12

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Vomiting	5
Pain	3
Pyrexia	3
Abscess	2
Anorexia	2
Depression	2
Lump (local)	2
Periorbital swelling	2
Vocalisation	2
Agitation	1
Alopecia (localised)	1

Lethargy	1
Leucopenia	1
Malaise	1
Muscle stiffness	1
Oedema	1
Site reaction	1
Tremor	1
Urticaria	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CANINE PARAINFLUENZA

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Coughing	2
Frothing at the mouth	1
Sneezing	1

CANINE PARAINFLUENZA TYPE 2*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
11	0	11

PRESENTING SIGN	INCIDENCE
Lethargy	4
Allergy	3
Diarrhoea	3
Facial oedema	3
Pyrexia	3
Vomiting	3
Anorexia	2
Restless	2
Ataxia	1
Pain	1
Paresis	1
Pupillary light reflex (abnormal)	1
Weakness	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CANINE PARAINFLUENZA VIRUS*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
109	55	54

PRESENTING SIGN	INCIDENCE
Lethargy	44
Pain	32
Vomiting	28
Anorexia	21
Facial oedema	18
Shaking	14
Coughing	11
Injection site reaction	9
Urticaria	9
Depression	5
Pyrexia	5
Erythema	4
Pale mucous membranes	4
Pruritis	4
Collapse	3
Swollen lips and face	3
Tremor	3
Anaphylaxis	2
Disorientation	2
Malaise	2
Periorbital swelling	2
Vocalisation	2

PRESENTING SIGN	INCIDENCE
Weakness	2
Wheals	2
Agitation	1
Alopecia (localised)	1
Anaphylactoid reaction	1
Ataxia	1
Bradycardia	1
Diarrhoea	1
Distress	1
Dyspnoea	1
Haemorrhagic gastroenteritis	1
Hives	1
Hypersalivation	1
Hypotension	1
Lump (local)	1
Nasal discharge	1
Respiratory problems	1
Site reaction	1
Sneezing	1
Tachypnoea	1
Thrombocytopenia	1
Unconscious	1
Urination	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines.

Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CANINE PARAINFLUENZA VIRUS - INACTIVATED*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
22	7	15

PRESENTING SIGN	INCIDENCE
Injection site reaction	14
Lump (local)	8
Pain	4
Pyrexia	3
Abscess	2
Lethargy	2
Anorexia	1
Collapse	1
Depression	1
Epistaxis	1
Facial oedema	1
Immune-mediated haemolytic anaemia	1
Leucopenia	1
Muscle stiffness	1
Oedema	1
Polyarthritis	1
Site reaction	1
Thrombocytopenia	1
Vomiting	1

CANINE PARVO VIRUS*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
20	2	18

PRESENTING SIGN	INCIDENCE
Lethargy	6
Vomiting	6
Facial oedema	4
Pyrexia	4
Allergy	3
Anorexia	3
Diarrhoea	3
Injection site reaction	2
Restless	2
Anaphylaxis	1
Ataxia	1
Coughing	1
Depression	1
Frothing at the mouth	1
Haemorrhagic gastroenteritis	1
Lack of effect	1
Lump (local)	1
Pain	1
Paresis	1
Pupillary light reflex (abnormal)	1
Weakness	1

CANINE PARVO VIRUS TYPE 2*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
82	53	29

PRESENTING SIGN	INCIDENCE
Lethargy	40
Pain	30
Vomiting	21
Facial oedema	17
Anorexia	16
Shaking	14
Urticaria	8
Injection site reaction	7
Erythema	4
Pale mucous membranes	4
Pruritis	4
Collapse	3
Depression	3
Pyrexia	3
Swollen lips and face	3
Disorientation	2
Tremor	2
Weakness	2
Wheals	2
Anaphylactoid reaction	1
Anaphylaxis	1
Ataxia	1

PRESENTING SIGN	INCIDENCE
Bradycardia	1
Coughing	1
Diarrhoea	1
Distress	1
Dyspnoea	1
Hives	1
Hypersalivation	1
Hypotension	1
Malaise	1
Site reaction	1
Site reaction (swelling)	1
Tachypnoea	1
Thrombocytopenia	1
Unconscious	1
Urination	1

CANINE PARVOVIRUS - LIVE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
16	5	11

PRESENTING SIGN	INCIDENCE
Injection site reaction	8
Lump (local)	6
Lethargy	3
Pain	3

Anorexia	2
Collapse	1
Epistaxis	1
Facial oedema	1
Immune-mediated haemolytic anaemia	1
Polyarthritis	1
Pyrexia	1
Thrombocytopenia	1

CANINE PARVO VIRUS STRAIN 154 - LIVE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
14	2	12

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Vomiting	5
Pain	3
Pyrexia	3
Abscess	2
Anorexia	2
Depression	2
Lump (local)	2
Periorbital swelling	2
Vocalisation	2
Agitation	1
Alopecia (localised)	1

PRESENTING SIGN	INCIDENCE
Lethargy	1
Leucopenia	1
Malaise	1
Muscle stiffness	1
Oedema	1
Site reaction	1
Tremor	1
Urticaria	1

The most reported side effects of vaccinations include vomiting, coughing, lethargy and diarrhoea. These occur very occasionally with most vaccines. Due to the low number of reports when taking into consideration the large number of dogs vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

CARBARYL

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Irritation (eye)	1
Red eyes	1
Swelling (local)	1

CARPROFEN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Azotaemia	1
Coagulopathy	1
Haematemesis	1
Hepatopathy	1
Lethargy	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Renal failure	1

CEFTIOFUR AS CEFTIOFUR HYDROCHLORIDE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Residue violation	1

CEFUROXIME SODIUM*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

CELLULASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	NUMBER OF REPORTS
Residue violation	1

CEPHALEXIN AS CEPHALEXIN MONOHYDRATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	1	1

PRESENTING SIGN	INCIDENCE
Lethargy	1
Vomiting	1

CHLAMYDOPHILIA FELIS BAKER STRAIN - LIVE, ATTENUATED*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	2	4

PRESENTING SIGN	INCIDENCE
Anorexia	3
Pain	3
Lethargy	2
Pyrexia	2
Behavioural change	1
Facial oedema	1
Malaise	1
Ocular discharge	1
Self trauma	1
Site reaction (swelling)	1
Sneezing	1
URTI	1

CHLORAMPHENICOL*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Allergy	1

CHLORFENVINPHOS*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

CHLORHEXIDINE GLUCONATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	2	1

PRESENTING SIGN	INCIDENCE
Hives	1
Hypersensitivity reaction	1
Pruritis	1

CHLORPHENIRAMINE MALEATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Bradycardia	1
Collapse	1
Seizure	1

CHLORPYRIFOS*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Lack of effect	2

CLAVULANIC ACID AS POTASSIUM CLAVULANATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Injection site reaction	2
Abscess	1
Lump (local)	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1

CLOMIPRAMINE HYDROCHLORIDE*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	0	3

PRESENTING SIGN	INCIDENCE
Anorexia	1
Constipation	1
Urinary retention	1

CLOSTRIDIUM BOTULINUM TYPE C TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1
Lack of effect	1
Paralysis	1

CLOSTRIDIUM BOTULINUM TYPE D TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1		1

PRESENTING SIGN	INCIDENCE
Death	1
Lack of effect	1
Paralysis	1

CLOSTRIDIUM CHAUVOEI - FORMOL CULTURE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

CLOSTRIDIUM CHAUVOEI - KILLED*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	0	6

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Lump (local)	1
Swelling (local)	1

CLOSTRIDIUM CHAUVOEI - KILLED*Caprine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

CLOSTRIDIUM CHAUVOEI - KILLED*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM CHAUVOEI - TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	0	6

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Lump (local)	1
Swelling (local)	1

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM NOVYI TYPE B – KILLED*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	0	6

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Lump (local)	1
Swelling (local)	1

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM NOVYI TYPE B - TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
7	0	7

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Death	1
Lump (local)	1
Swelling (local)	1

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM PERFRINGENS TYPE D TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
7	0	7

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Death	1
Lump (local)	1
Swelling (local)	1

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM SEPTICUM - TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
7	0	7

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Death	1
Lump (local)	1
Swelling (local)	1

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM TETANI - ANTITOXIN*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Death	2
Colic	1
Oedema	1
Stiffness	1

PRESENTING SIGN	INCIDENCE
Urticaria	1

CLOSTRIDIUM TETANI - TOXOID*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
7	0	7

PRESENTING SIGN	INCIDENCE
Injection site reaction	5
Abscess	1
Death	1
Lump (local)	1
Swelling (local)	1

Caprine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Abscess	1
Injection site reaction	1
Lump (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Lethargy	1
Lump (local)	1

CLOSTRIDIUM TETANI UF TOXOID*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1
Stiffness	1

CLOTRIMISOLE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	0	3

PRESENTING SIGN	INCIDENCE
Deafness	3

COBALT EDTA*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

COPPER SULFATE*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Diarrhoea	1

CORONA VIRUS*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

CYCLOSPORIN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
25	18	7

PRESENTING SIGN	INCIDENCE
Vomiting	14
Diarrhoea	7
Lethargy	4
Agitation	2
Gingival hyperplasia	2
Hyperactivity	2
Tachypnoea	2
Abdominal pain	1
Alopecia	1
Anorexia	1
Ataxia	1
Behavioural change	1
Dehydration	1
Erythema	1
Irritation (skin)	1
Lack of effect	1
Muscle twitching	1
Pruritis	1
Restless	1
Tachycardia	1

CYPERMETHRIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

DELTAMETHRIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	2	2

PRESENTING SIGN	INCIDENCE
Behavioural change	2
Irritation (skin)	1
Lack of effect	1
Milk production decrease	1
Site reaction	1

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Behavioural change	1
Colic	1
Sweating	1

DEOXYCORTONE PIVALATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Pain	1

DERACOXIB*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Haematemesis	1
Vomiting	1

DESLORELIN AS DESLORELIN ACETATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
17	7	10

PRESENTING SIGN	INCIDENCE
Lack of effect	6
Allergy	2
Behavioural change	2
Low efficacy	2
Site reaction	2
Abscess	1

PRESENTING SIGN	INCIDENCE
Alopecia	1
Incontinence	1
Reproduction disorder	1

DEXTROMETHORPHAN HYDROBROMIDE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Bradycardia	1
Collapse	1
Seizure	1

DIAZINON*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	0	4

PRESENTING SIGN	INCIDENCE
Lack of effect	4

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Lack of effect	2

DICYCLANIL*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
9	0	9

PRESENTING SIGN	INCIDENCE
Lack of effect	9
Flystrike	2

DIFLUBENZURON*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
102	39	63

PRESENTING SIGN	INCIDENCE
Lack of effect	102

Diflubenzuron is an insect growth-regulating compound (IGR). An IGR is a material that controls the life cycle of pests such as cockroaches and fleas by inhibiting maturation of the pests. The sheep and wool industry rely heavily on the use of the insect growth regulator group of chemicals (IGRs) for treating lice. Unfortunately there are lice with reduced susceptibility to IGRs.

DIHYDROSEPTROMYCIN AS THE SULFATE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

DOXYCYCLINE AS DOXYCYCLINE MONOHYDRATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Hepatopathy	2

EIMERIA ACERVULINA OOCYSTS*Avian*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

EIMERIA MAXIMA OOCYSTS*Avian*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

EIMERIA NECATRIX OOCYSTS*Avian*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

EIMERIA TENELLA OOCYSTS*Avian*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

EMODEPSIDE*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
29	28	1

PRESENTING SIGN	INCIDENCE
Alopecia (localised)	25
Ataxia	1
Behavioural change	2
Burn(s)	1
Erythema	1

PRESENTING SIGN	INCIDENCE
Inflammation	1
Irritation (skin)	1
Lesions	1
Rash	1

ENROFLOXACIN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	3	1

PRESENTING SIGN	INCIDENCE
Erythema	2
Hypersalivation	1
Inflammation	1
Injection site reaction	1
Swelling (local)	1
Ulceration	1
Vomiting	1

EPHEDRINE HYDROCHLORIDE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Bradycardia	1
Collapse	1
Seizure	1

EPRINOMECTIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	0	4

PRESENTING SIGN	INCIDENCE
Lack of effect	4

FEBANTEL*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
7	4	3

PRESENTING SIGN	INCIDENCE
Vomiting	3
Hyperactivity	2
Diarrhoea	1
Facial oedema	1
Hyperexcitable	1
Lethargy	1
Mydriasis	1
Restless	1
Shaking	1
Urticaria	1

FELINE CALICIVIRUS - INACTIVATED*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
24	12	12

PRESENTING SIGN	INCIDENCE
Lethargy	11
Anorexia	10
Pain	8
Pyrexia	6
Diarrhoea	5
Vomiting	5
Injection site reaction	4
Death	2
Erythema	2
Facial oedema	2
Pruritis	2
Alopecia (localised)	1
Anaphylaxis	1
Behavioural change	1
Depression	1
Gastroenteritis	1
Haematemesis	1
Hypotension	1
Malaise	1
Muscle stiffness	1
Ocular discharge	1
Pulmonary oedema	1

PRESENTING SIGN	INCIDENCE
Recumbency	1
Respiratory problems	1
Self trauma	1
Site reaction (swelling)	1
Sneezing	1
URTI	1

The most reported side effects of vaccinations in cats include lethargy, anorexia and pyrexia. These occur very occasionally with most vaccines. Due to the low number of reports when taking into consideration the large number of cats vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

FELINE LEUKAEMIA VIRUS – INACTIVATED

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	1	1

PRESENTING SIGN	INCIDENCE
Pain	2
Anorexia	1
Lethargy	1

FELINE PANLEUCOPENIA VIRUS - INACTIVATED

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
24	12	12

PRESENTING SIGN	INCIDENCE
Lethargy	11

PRESENTING SIGN	INCIDENCE
Anorexia	10
Pain	8
Pyrexia	6
Diarrhoea	5
Vomiting	5
Injection site reaction	4
Death	2
Erythema	2
Facial oedema	2
Pruritis	2
Alopecia (localised)	1
Anaphylaxis	1
Behavioural change	1
Depression	1
Gastroenteritis	1
Haematemesis	1
Hypotension	1
Malaise	1
Muscle stiffness	1
Ocular discharge	1
Pulmonary oedema	1
Recumbency	1
Respiratory problems	1
Self trauma	1
Site reaction (swelling)	1
Sneezing	1
URTI	1

The most reported side effects of vaccinations in cats include lethargy, anorexia and pyrexia. These occur very occasionally with most vaccines. Due to the low number of reports when taking into consideration the large number of cats vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

FELINE RHINOTRACHEITIS VIRUS - INACTIVATED

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
24	12	12

PRESENTING SIGN	INCIDENCE
Lethargy	11
Anorexia	10
Pain	8
Pyrexia	6
Diarrhoea	5
Vomiting	5
Injection site reaction	4
Death	2
Erythema	2
Facial oedema	2
Pruritis	2
Alopecia (localised)	1
Anaphylaxis	1
Behavioural change	1
Depression	1
Gastroenteritis	1
Haematemesis	1
Hypotension	1

PRESENTING SIGN	INCIDENCE
Malaise	1
Muscle stiffness	1
Ocular discharge	1
Pulmonary oedema	1
Recumbency	1
Respiratory problems	1
Self trauma	1
Site reaction (swelling)	1
Sneezing	1
URTI	1

The most reported side effects of vaccinations in cats include lethargy, anorexia and pyrexia. These occur very occasionally with most vaccines. Due to the low number of reports when taking into consideration the large number of cats vaccinated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

FENTHION

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Site reaction	1

FIPRONIL*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

Fipronil is a broad-spectrum phenyl pyrazole insecticide acting on the nervous system of insects by contact or ingestion. These are relatively new products in the market place and have a very high volume of sales. Fipronil is currently under review. Progress of the review can be monitored on the APVMA website (<http://www.apvma.gov.au/chemrev/ChemRevProgram.shtml>).

FIROCOXIB*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
10	2	8

PRESENTING SIGN	INCIDENCE
Lethargy	4
Vomiting	4
Anorexia	2
Blood in faeces	2
Collapse	2
Death	2
Diarrhoea	2
Melaena	2
Abdominal pain	1
Azotaemia	1
Thrombocytopenia	1
Ulceration (stomach)	1

FLUAZURON*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

FLUMETHRIN*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Irritation (skin)	1
Rolling	1

FORMALIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Injection site reaction	2
Anorexia	1
Oedema	1

FUNGAL PROTEASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

GENTAMYCIN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	0	3

PRESENTING SIGN	INCIDENCE
Deafness	3

HEPATITIS CANINE = CANINE ADENOVIRUS*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

HYOSCINE AS HYOSCINE METHOBROMIDE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

IMIDACLOPRID*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
274	237	37

PRESENTING SIGN	INCIDENCE
Irritation (skin)	98
Behavioural change	62
Restless	44
Lethargy	39
Paraesthesia	33
Agitation	32
Site reaction	30
Vomiting	26
Anorexia	17
Lack of effect	17
Shaking	17
Inflammation	15
Depression	14
Dermatitis	14
Erythema	14

PRESENTING SIGN	INCIDENCE
Alopecia (localised)	12
Rolling	12
Rubbing	12
Self trauma	12
Hyperexcitable	11
Distress	10
Scabs	9
Diarrhoea	8
Panting	8
Ataxia	6
Rash	5
Pruritis	4
Lesions	3
Red eyes	3
Urticaria	3
Adipsia	2
Burn(s)	2
CNS dysfunction	2
Polydipsia	2
Pustules	2
Respiratory problems	2
Tick paralysis	2
Walking (difficult)	2
Welts	2
Abscess	1
Blisters	1
Blood in faeces	1

PRESENTING SIGN	INCIDENCE
Burning sensation	1
Conjunctivitis	1
Crusting skin	1
Epiphora	1
Excitation	1
Facial oedema	1
Hallucinating	1
Hyperactivity	1
Hyperaesthesia	1
Hypothermia	1
Incontinence	1
Irritation (ear)	1
Irritation (eye)	1
Lump (local)	1
Muscle twitching	1
Nausea	1
Nil	1
Otitis externa	1
Paresis	1
Site reaction (swelling)	1
Skin slough	1
Spasm	1
Toxicity	1
Tremor	1
Unknown	1
Vocalisation	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
53	46	7

PRESENTING SIGN	INCIDENCE
Alopecia (localised)	23
Dermatitis	6
Lesions	5
Alopecia	4
Vomiting	4
Behavioural change	3
Hypersalivation	3
Rash	3
Scabs	3
Anorexia	2
Ataxia	2
Frothing at the mouth	2
Inflammation	2
Lethargy	2
Self trauma	2
Site reaction	2
Agitation	1
Blindness	1
CNS dysfunction	1
Depression	1
Distress	1
Erythema	1
Hyperaesthesia	1

PRESENTING SIGN	INCIDENCE
Irritation (skin)	1
Nil	1
Polydipsia	1
Tachypnoea	1
Tremor	1
Ulceration	1

INACTIVATED SALMONELLA DUBLIN & TYPHIMURIUM ANTIGENS

Bovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Scouring	1

INFECTIOUS LARYNGOTRACHEITIS VIRUS STRAIN S.A.2

Avian

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

INSULIN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Oedema	1
Site reaction	1
Swelling (local)	1

IVERMECTIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	1	3

PRESENTING SIGN	INCIDENCE
Site reaction	2
Alopecia (localised)	1
Dermatitis	1
Lack of effect	1
Lesions	1

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	0	3

PRESENTING SIGN	INCIDENCE
Diarrhoea	2
Vomiting	2

PRESENTING SIGN	INCIDENCE
Abdominal pain	1
Depression	1

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	4	0

PRESENTING SIGN	INCIDENCE
Hypersalivation	2
Swelling (local)	2
Anorexia	1
Lethargy	1
Oedema	1
Site reaction (swelling)	1
Swollen lips and face	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	1	3

PRESENTING SIGN	INCIDENCE
Lack of effect	4

LEPTOSPIRA BORGPETERSENII SEROVAR HARDJO*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

LEPTOSPIRA INTERROGANS SEROVAR POMONA*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

LEPTOSPIROSIS - DOG - LEPTOSPIRA ICTEROHAEMORRHAGIAE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

LEVAMISOLE HYDROCHLORIDE*Avian*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Death	1
Pale mucous membranes	1

LINCOMYCIN AS LINCOMYCIN HYDROCHLORIDE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Cyanosis	1
Vomiting	1

LUFENURON*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
11	4	7

PRESENTING SIGN	INCIDENCE
Diarrhoea	4
Vomiting	4
Anorexia	2
Ataxia	2
Distress	2
Lack of effect	2
Convulsions	1
Haematology (abnormal)	1
Hyperaesthesia	1
Hypersalivation	1
Incontinence	1
Lethargy	1
Miosis	1
Panting	1
Somnolence	1
Stiffness	1
Tachypnoea	1
Weakness	1

M.HYOPNEUMONIA – INACTIVATED WHOLE CELL CULTURE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Death	2
Respiratory problems	2
Vomiting	2
Ataxia	1
Behavioural change	1

MELALEUCA OIL*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Irritation (skin)	1

MELOXICAM*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	1	1

PRESENTING SIGN	INCIDENCE
Anaphylactoid reaction	2

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	0	3

PRESENTING SIGN	INCIDENCE
Vomiting	3
Anorexia	2
Abdominal pain	1
Azotaemia	1
Dehydration	1
Diarrhoea	1
Haemorrhagic gastroenteritis	1
Illthrift	1
Melaena	1
Neutrophilia	1
Renal failure	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Coagulopathy	1
Hypotension	1
Renal failure	1

METHOPRENE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Lack of effect	2

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	1	2

PRESENTING SIGN	INCIDENCE
Ataxia	1
Hypersalivation	1
Incoordination	1
Lethargy	1

MICONAZOLE NITRATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	2	1

PRESENTING SIGN	INCIDENCE
Hives	1
Hypersensitivity reaction	1
Pruritis	1

MILBEMYCIN OXIME*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
16	6	10

PRESENTING SIGN	INCIDENCE
Vomiting	5
Diarrhoea	4
Ataxia	3
Lethargy	3
Anorexia	2
Distress	2
Lack of effect	2
Convulsions	1
Epistaxis	1
Facial oedema	1
Haematology (abnormal)	1
Hyperaesthesia	1
Hypersalivation	1
Incontinence	1
Miosis	1
Panting	1
Pruritis	1
Somnolence	1
Stiffness	1
Tachypnoea	1
Walking (difficult)	1
Weakness	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	1	1

PRESENTING SIGN	INCIDENCE
Ataxia	1
Lethargy	1
Vomiting	1

MORAXELLA BOVIS*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
22	2	20

PRESENTING SIGN	INCIDENCE
Lack of effect	19
Anaphylaxis	1
Bloat	1
Death	1
Dyspnoea	1
Hypersalivation	1
Injection site reaction	1
Lump (local)	1
Tachycardia	1

MOXIDECTIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	3	3

PRESENTING SIGN	INCIDENCE
Ataxia	4
Recumbency	3
Death	2
Hypersalivation	2
Blood in faeces	1
Convulsions	1
Depression	1
Frothing at the mouth	1
Frothing at the nose	1
Haemorrhage	1
Lack of effect	1
Mydriasis	1
Respiratory problems	1
Swelling (local)	1

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
50	21	29

PRESENTING SIGN	INCIDENCE
Vomiting	19
Lethargy	12

PRESENTING SIGN	INCIDENCE
Facial oedema	6
Diarrhoea	5
Urticaria	5
Alopecia (localised)	4
Behavioural change	3
Irritation (skin)	3
Pruritis	3
Shaking	3
Site reaction	3
Agitation	2
Anorexia	2
Burn(s)	2
Depression	2
Anaphylactoid reaction	1
Anaphylaxis	1
Conjunctivitis	1
Dermatitis	1
Erythema	1
Haemorrhagic gastroenteritis	1
Incontinence	1
Injection site reaction	1
Lack of effect	1
Lesions	1
Nil	1
Otitis externa	1
Pustules	1
Pyrexia	1

PRESENTING SIGN	INCIDENCE
Red eyes	1
Respiratory problems	1
Swollen lips and face	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
34	29	5
PRESENTING SIGN	INCIDENCE	
Alopecia (localised)	12	
Alopecia	4	
Rash	3	
Scabs	3	
Vomiting	3	
Anorexia	2	
Ataxia	2	
Frothing at the mouth	2	
Hypersalivation	2	
Inflammation	2	
Lethargy	2	
Behavioural change	1	
Blindness	1	
CNS dysfunction	1	
Depression	1	
Distress	1	
Hyperaesthesia	1	
Irritation (skin)	1	
Lesions	1	

Nil	1
Polydipsia	1
Self trauma	1
Tremor	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Lack of effect	1
Lethargy	1
Stiffness	1
Walking (difficult)	1

Moxidectin is often used in conjunction with other products, resulting in a higher incidence of reporting. These products have a very high volume of sales and several new products have been released. A few products have a reporting incidence approaching warning levels and these products are being closely monitored.

Note : Moxidectin and Moxidectin Microspheres are reported under the active Moxidectin in this report.

MYCOPLASMA HYOPNEUMONIAE – INACTIVATED ANTIGEN*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Anaphylactoid reaction	1
Death	1
Vomiting	1

MYO-INOSITOL-HEXAPHOSPHATE PHOSPHOHYDROLASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

NIGERGOLINE FREEZE DRIED*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lethargy	1
Vomiting	1

NICLOSAMIDE*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	1	1

PRESENTING SIGN	INCIDENCE
Behavioural change	1
Diarrhoea	1
Vomiting	2

NICLOSAMIDE MONOHYDRATE - MICRONISED*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Illness	1

NITENPYRAM*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Hypersensitivity reaction	1
Lethargy	1
Oedema	1
Urticaria	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
5	4	1

PRESENTING SIGN	INCIDENCE
Irritation (skin)	4
Panting	3
Agitation	2
Distress	2
Pyrexia	1

PRESENTING SIGN	INCIDENCE
Tachycardia	1
Tachypnoea	1

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
8	1	7

PRESENTING SIGN	INCIDENCE
Erythema	1
Lack of effect	6
Restless	1
Site reaction	1
Tick paralysis	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	1	3

PRESENTING SIGN	INCIDENCE
Ataxia	1
Hypersalivation	1
Illness	1
Incoordination	1
Lethargy	1

OATMEAL EXTRACT*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	2	0

PRESENTING SIGN	INCIDENCE
Irritation (eye)	1

OESTRADIOL 17-BETA*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Prolapse	2

OXANTEL EMBONATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

OXFENDAZOLE*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

OXYTETRACYCLINE HYDROCHLORIDE*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Ataxia	1
Collapse	1
Death	1
Oedema	1
Swollen ears and face	1

PARVOVIRUS - LIVE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

PECTINASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

PENTOBARBITONE SODIUM*Caprine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Lack of effect	1

PERMETHRIN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
26	25	1

PRESENTING SIGN	INCIDENCE
Paraesthesia	21
Dermatitis	6
Behavioural change	5
Alopecia (localised)	2
Lethargy	2
Site reaction	2
Ataxia	1
Depression	1
Epiphora	1
Panting	1
Restless	1
Vomiting	1

Permethrin is a common synthetic chemical, widely used as an insecticide, acaricide, and insect repellent. Permethrin is often used in conjunction with other products, resulting in a higher incidence of reporting. These products have a very high volume of sales.

PERMETHRIN (25:75: :CIS:TRANS)*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Lack of effect	2

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Hypersensitivity reaction	1
Welts	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Seizure	1

PERMETHRIN (40:60: :CIS:TRANS)*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
206	187	19

PRESENTING SIGN	INCIDENCE
Irritation (skin)	96

PRESENTING SIGN	INCIDENCE
Behavioural change	48
Restless	43
Agitation	30
Lethargy	30
Site reaction	26
Lack of effect	16
Inflammation	15
Anorexia	14
Erythema	14
Shaking	14
Vomiting	14
Depression	12
Paraesthesia	12
Rolling	12
Rubbing	12
Self trauma	12
Hyperexcitable	11
Distress	10
Scabs	9
Dermatitis	7
Panting	6
Rash	6
Ataxia	4
Alopecia (localised)	3
Blisters	3
Diarrhoea	3
Adipsia	2

PRESENTING SIGN	INCIDENCE
CNS dysfunction	2
Lesions	2
Polydipsia	2
Pruritis	2
Red eyes	2
Respiratory problems	2
Tick paralysis	2
Walking (difficult)	2
Welts	2
Abscess	1
Allergy	1
Blood in faeces	1
Burning sensation	1
Convulsions	1
Crusting skin	1
Excitation	1
Frothing at the mouth	1
Hallucinating	1
Hyperactivity	1
Hyperaesthesia	1
Hypothermia	1
Irritation (ear)	1
Irritation (eye)	1
Lump (local)	1
Muscle twitching	1
Nausea	1
Paresis	1

PRESENTING SIGN	INCIDENCE
Pustules	1
Site reaction (swelling)	1
Skin slough	1
Spasm	1
Toxicity	1
Unknown	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Poisoning	1

PIMOBENDAN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Diarrhoea	1
Melaena	1

PIPERONYL BUTOXIDE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
5	0	5

PRESENTING SIGN	INCIDENCE
Lack of effect	5

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
10	1	9

PRESENTING SIGN	INCIDENCE
Lack of effect	7
Corneal ulcer	1
Erythema	1
Irritation (eye)	1
Restless	1
Site reaction	1
Tick paralysis	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
5	1	4

PRESENTING SIGN	INCIDENCE
Ataxia	1
Hypersalivation	1
Illness	1
Incoordination	1

PRESENTING SIGN	INCIDENCE
Lethargy	1
Seizure	1

POLYMYXIN B SULFATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Allergy	1

PRAZIQUANTEL*Avian*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1		1

PRESENTING SIGN	INCIDENCE
Death	1

Canine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
23	10	13

PRESENTING SIGN	INCIDENCE
Vomiting	8
Diarrhoea	5
Lethargy	4
Ataxia	3

PRESENTING SIGN	INCIDENCE
Lack of effect	3
Anorexia	2
Distress	2
Facial oedema	2
Hyperactivity	2
Convulsions	1
Haematology (abnormal)	1
Hyperaesthesia	1
Hyperexcitable	1
Hypersalivation	1
Incontinence	1
Miosis	1
Mydriasis	1
Panting	1
Pruritis	1
Restless	1
Shaking	1
Somnolence	1
Stiffness	1
Tachypnoea	1
Urticaria	1
Walking (difficult)	1
Weakness	1

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	4	0

PRESENTING SIGN	INCIDENCE
Hypersalivation	2
Swelling (local)	2
Anorexia	1
Lethargy	1
Oedema	1
Site reaction (swelling)	1
Swollen lips and face	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
34	32	2

PRESENTING SIGN	INCIDENCE
Alopecia (localised)	25
Ataxia	4
Behavioural change	2
Lethargy	2
Burn(s)	1
Disorientation	1
Erythema	1
Incoordination	1

PRESENTING SIGN	INCIDENCE
Inflammation	1
Irritation (skin)	1
Lesions	1
Rash	1
Vomiting	1

Praziquantel is a systemic anthelmintic used primarily to treat worm infections. Due to the low number of reports when taking into consideration the large number of animals treated each year, no further regulatory action is required other than continuing monitoring for future adverse experience reports.

PROCAINE PENICILLIN

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	3	1

PRESENTING SIGN	INCIDENCE
Death	3
Ataxia	2
Anaphylaxis	1
Restless	1
Shaking	1
Stiffness	1

PROPOFOL*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
36	28	8

PRESENTING SIGN	INCIDENCE
Facial oedema	17
Erythema	9
Hives	9
Welts	8
Bradycardia	5
Cardiac arrest	3
Urticaria	3
Wheals	3
Hypersensitivity reaction	2
Anaphylaxis	1
Apnoea	1
Cyanosis	1
Death	1
Dyspnoea	1
Hypotension	1
Paddling	1
Pain	1
Pulmonary oedema	1
Rash	1
Site reaction (swelling)	1
Swelling (local)	1

PYRANTEL AS PYRANTEL EMBONATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
11	4	7

PRESENTING SIGN	INCIDENCE
Vomiting	5
Diarrhoea	3
Hyperactivity	2
Abdominal pain	1
Depression	1
Facial oedema	1
Hyperexcitable	1
Lack of Effect	1
Lethargy	1
Mydriasis	1
Restless	1
Shaking	1
Urticaria	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
6	4	2

PRESENTING SIGN	INCIDENCE
Ataxia	2
Behavioural change	1
Diarrhoea	1
Disorientation	1

PRESENTING SIGN	INCIDENCE
Illness	1
Incoordination	1
Lethargy	1
Vomiting	1

PYRETHRINS*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
10	1	9

PRESENTING SIGN	INCIDENCE
Lack of effect	7
Corneal ulcer	1
Erythema	1
Irritation (eye)	1
Restless	1
Site reaction	1
Tick paralysis	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	1	3

PRESENTING SIGN	INCIDENCE
Ataxia	1
Hypersalivation	1

PRESENTING SIGN	INCIDENCE
Illness	1
Incoordination	1
Lethargy	1

PYRIPROXYFEN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	1	2

PRESENTING SIGN	INCIDENCE
Allergy	1
Blisters	1
Erythema	1
Rash	1
Site reaction	1

(S)-METHOPRENE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Illness	1

(S)-methoprene is often used in conjunction with other products resulting in a higher incidence of reporting. (S)-methoprene is a pesticide that acts as a juvenile hormone mimic, disrupting the development of insects and preventing the larvae from emerging as adults.

SELAMECTIN*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
9	6	3

PRESENTING SIGN	INCIDENCE
Alopecia (localised)	4
Site reaction	4
Pruritis	2
Erythema	1

PRESENTING SIGN	INCIDENCE
Facial oedema	1
Irritation (skin)	1
Shaking	1
Tremor	1
Urticaria	1

Feline

NUMBER OF REPORTS	PROBABLE	POSSIBLE
32	31	1

PRESENTING SIGN	INCIDENCE
Alopecia (localised)	29
Site reaction	9
Dermatitis	2
Behavioural change	1
Lethargy	1
Pruritis	1

SELENIUM AS SODIUM SELENATE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Swelling (local)	1

Ovine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	3	1

PRESENTING SIGN	INCIDENCE
Injection site reaction	1
Death	1
Lack of effect	1
Lethargy	2
Lump (local)	1
Stiffness	1
Walking (difficult)	1

SILVER SULFADIAZINE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Erythema	2
Inflammation	1
Swelling (local)	1
Ulceration	1

SODIUM PENTOSAN POLYSULFATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
4	1	3

PRESENTING SIGN	INCIDENCE
Agitation	1
Anorexia	1
Ataxia	1
Behavioural change	1
Diarrhoea	1
Lethargy	2
Pain	1
Pyrexia	1
Vomiting	1

SPECTINOMYCIN AS SPECTINOMYCIN SULFATE*Canine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Cyanosis	1
Vomiting	1

SPINOSAD*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
5	1	4

PRESENTING SIGN	INCIDENCE
Lack of effect	5

SULFADIAZINE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

Equine

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Anaphylaxis	2
Collapse	1
Death	1

SULFADIMIDINE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

TRICLABENDAZOLE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	0	2

PRESENTING SIGN	INCIDENCE
Dermatitis	1
Lack of effect	1

TRIFLUMURON*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
11	10	1

PRESENTING SIGN	INCIDENCE
Lack of effect	11

TRIMETHOPRIM*Equine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Anaphylaxis	2
Collapse	1
Death	1

VITAMIN A*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Diarrhoea	1

VITAMIN B1 – THIAMINE HYDROCHLORIDE*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

VITAMIN D3*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Diarrhoea	1

VITAMIN E*Feline*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Diarrhoea	1

XYLANASE*Porcine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Residue violation	1

ZETA-CYPERMETHRIN*Bovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
5	0	5

PRESENTING SIGN	INCIDENCE
Lack of effect	5

ZINC EDTA*Ovine*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Death	1

3 VETERINARY - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (HUMAN)

3.1 Adverse experience report summaries involving humans listed by active constituent

The following information is contained in this section:

Active constituent name

Each active constituent is listed alphabetically, with a summary of the adverse experience reports. It is important to note that the number of adverse experience reports and the presenting signs observed may be listed under more than one active constituent if they refer to a product that contains multiple active constituents.

Number of reports

Only adverse experience reports that were classified by the APVMA during the calendar year 2007, as being either probable or possible have been included in these lists. The summary table indicates how many reports were classified as probable and how many were classified as possible.

Presenting signs

All observed clinical signs for reports that were classified as probable and possible are listed in order of frequency.

It is important to note that multiple clinical signs may have been noted in some individual reports. Therefore the list of clinical signs observed does not relate directly to the total number of reports received.

3.2 Veterinary - Human AERs

CHLORFENVINPHOS

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Dizziness	1
Shaking	1

CLOSTRIDIUM CHAUVOEI - TOXOID

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Needle stick injury	1

CLOSTRIDIUM CHAUVOEI TOXIOD AND INACTIVATED CELLS

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Needle stick injury	1

CLOSTRIDIUM NOVYI TYPE B TOXIOD AND INACTIVATED CELLS

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1		1

Presenting sign	Incidence
Needle Stick	1

CLOSTRIDIUM PERFRINGES TYPE D TOXOID

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Needle stick injury	1

CLOSTRIDIUM SEPTICUM - TOXOID

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Needle stick injury	1

CLOSTRIDIUM TETANI - TOXOID*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Needle stick injury	1

COLLOIDAL OATMEAL*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Erythema	1
Pruritis	1

CORYNEBACTERIUM PSEUDOTUBERCULOSIS TOXOID AND INACTIVATE*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Needle stick injury	1

CYPERMETHRIN

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Dizziness	1
Shaking	1

FIPRONIL

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Inflammation	1
Irritation (eye)	1
Red eyes	1

IMIDACLOPRID

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
3	3	0

PRESENTING SIGN	INCIDENCE
Agitation	2
Behavioural change	1

PRESENTING SIGN	INCIDENCE
Burning sensation	1
Irritation (skin)	1
Muscle twitching	1
Restless	1

MOXIDECTIN*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
2	2	0

PRESENTING SIGN	INCIDENCE
Agitation	1
Behavioural change	1
Burning sensation	1

MYCOBACTERIUM PARATUBERCULOSIS*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Erythema	1

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	1

PRESENTING SIGN	INCIDENCE
Allergy	1

PERMETHRIN (40:60: :CIS:TRANS)

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Agitation	1
Irritation (skin)	1
Muscle twitching	1
Restless	1

PIPERONYL BUTOXIDE

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Allergy	1

PYRETHRINS*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Allergy	1

(S)-METHOPRENE*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Inflammation	1
Irritation (eye)	1
Red eyes	1

SELAMECTIN*Human*

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	INCIDENCE
Burning sensation	1

4 AGRICULTURE - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (STANDARD)

4.1 Adverse experience report summaries involving crop damage, domestic animal harm, environmental damage or lack of efficacy listed by active constituent

The following information is contained in this section:

Active constituent name

- Each active constituent is listed alphabetically, with a summary of the adverse experience reports.
- It is important to note that the number of adverse experience reports and the presenting signs observed may be listed under more than one active constituent if they refer to a product that contains multiple active constituents.

Number of reports

- Only adverse experience reports that were classified by the APVMA during the calendar year 2007, as being either probable or possible have been included in these lists. The summary table indicates how many reports were classified as probable and how many were classified as possible.

Presenting signs

- All observed effects for reports that were classified as probable and possible are listed in order of frequency.
- It is important to note that multiple adverse effects have been noted in some individual reports. Therefore the list of observed effects does not relate directly to the total number of reports received.

4.2 Agriculture Chemical - Standard AERs

BACILLUS THURINGIENSIS SUBSP KURSTAKI DELTA ENDOTOXINS A

Cotton

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Crop damage	1

BUPROFEZIN

Table Grapes

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	0	1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

DIURON

Water / Pond

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1		1

PRESENTING SIGN	INCIDENCE
Lack of effect	1

INDOXACARB (25:75)

Canola

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	

PRESENTING SIGN	INCIDENCE
Residue violation	1

MCPA PRESENT AS THE POTASSIUM SALT

Cotton

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	

PRESENTING SIGN	INCIDENCE
Crop damage	1

TERBUTRYN

Cotton

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	

PRESENTING SIGN	INCIDENCE
Crop damage	1

5 AGRICULTURE - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (HUMAN)

5.1 Adverse experience report summaries involving humans listed by active constituent

The following information is contained in this section:

Active constituent name

Each active constituent is listed alphabetically, with a summary of the adverse experience reports.

It is important to note that the number of adverse experience reports and the presenting signs observed may be listed under more than one active constituent if they refer to a product that contains multiple active constituents.

Number of reports

Only adverse experience reports that were classified by the APVMA during the calendar year 2007, as being either probable or possible have been included in these lists. The summary table indicates how many reports were classified as 'probable' and how many were classified as possible.

Presenting signs

All observed clinical signs for reports that were classified as probable and possible are listed in order of frequency.

It is important to note that multiple adverse effects have been noted in some individual reports. Therefore the list of observed effects does not relate directly to the total number of reports received.

5.2 Agriculture Chemical - Human AERs

BIFENTHRIN

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	0

PRESENTING SIGN	NUMBER OF REPORTS
Burning sensation	1
Dyspnoea	1
Headache	1
Nasal discharge	1
Numbness	1
Ocular discharge	1

GLYPHOSATE PRESENT AS THE POTASSIUM SALT

Human

NUMBER OF REPORTS	PROBABLE	POSSIBLE
1	1	

PRESENTING SIGN	INCIDENCE
Irritation (eye)	1
Red eyes	1

This page has been intentionally left blank

GLOSSARY

Adipsia	Absence of thirst or abnormal avoidance of drinking
Alopecia	Absence of hair from areas where it is normally present
Analgesic	Pain relieving treatment
Anaphylactoid	An anaphylactic-type reaction
Anaphylaxis/anaphylactic	An exaggerated allergic reaction of an animal to a foreign protein or other substances
Anorexia	Lack or loss of appetite
Anthelmintic	An agent destructive to worms
Antimicrobial	An agent that kills micro-organisms or suppresses their multiplication or growth
Ataxia	Unsteady walking action due to muscular incoordination
Bradycardia	Excessive slowness in the action of the heart
Coagulopathy	Any disorder of blood coagulation
Colic	A general term for abdominal pain
Conjunctivitis	Conjunctivitis is the inflammation of the conjunctiva, a thin, delicate membrane that covers the eyeball and lines the eyelid
Cyanosis	Cyanosis is a physical sign causing bluish discoloration of the skin and mucous membranes due to a lack of oxygen in the blood
Dermatitis	Inflammation of the skin
Dyspnoea	Laboured breathing
Epiphora	Diseases of the lacrimal apparatus
Epistaxis	Bleeding from the nose
Erythema	Abnormal redness of the skin due to local congestion, as in inflammation
Fasciculation	Involuntary contractions or twitchings of groups of muscle fibers
Folliculitis	Inflammation of the follicles
Haematemesis	Vomiting of blood
Haemorrhage	Bleeding
Hepatopathy	Disease or disorder of the liver
Hypersalivation	Excessive salivation
Hypersensitivity	An excessive reaction to an allergen

Intramammary	Within or into the mammary gland
Jaundice	Yellowish staining of the skin and mucous membranes
Melaena	The passage of dark stools due to haemorrhage in the stomach or small intestine
Mydriasis	Unusual state of dilatation of pupil of the eye
Nausea	Unpleasant sensation in the stomach with a tendency to vomit
Necrosis	Pathological process associated with severe cellular trauma
Oedematous	Abnormal accumulation of fluid in body cavities and under the skin
Paraesthesia	An abnormal sensation
Parasiticide	An agent that is destructive to parasites
Periorbital	Surrounding the eyes
Petechiae	Purplish or brownish red discoloration, caused by hemorrhage into the tissues
Preputial	Of or pertaining to the prepuce
Prolapse	To fall or slip out of place
Pruritis	Irritation and intense itching
Pyrexia	High fever
Rales	Abnormal respiratory sound heard on auscultation, indicating some pathologic condition
Registrant	The commercial party that is responsible for the marketing of the product
Seizure	A sudden attack, as of disease or epilepsy
Seroma	A collection of serum in the body, producing a tumor-like mass
Somnolence	State of sleepiness or unnatural drowsiness
Tachycardia	Excessive rapidity in the action of the heart
Tachypnoea	Rapid shallow breaths
Tenesmus	Ineffectual and painful straining in an attempt to urinate or defecate
Thrombocytopenia	Decrease in the number of blood platelets
Urticaria	Vascular reaction of the skin as a result of contact with a chemical or may be immunologically based.
Wheals	A small swelling on the skin, as from an insect bite, that usually itches or burns
Withholding period	The time interval after the withdrawal of a drug or chemical use, to either the time of re-entry, harvesting or use of an animal or animal product for human consumption

LIST OF ACTIVE CONSTITUENTS

EXECUTIVE SUMMARY	1
1 INTRODUCTION	3
1.1 Program outline	3
1.2 What is an adverse experience?	3
Adverse Experiences - Serious and Minor	4
1.3 Who can report an adverse experience?	4
1.4 How to report an adverse experience?	5
1.5 Benefits of the AERP	5
Benefits to the community	5
Benefits to States and Territories	5
1.6 Evaluation of adverse experience reports	5
1.7 Classification of adverse experience reports	6
Probable	6
Possible	6
Probable or Possible Off-label	6
Unlikely	7
Unknown	7
1.8 Corrective action determination	7
1.9 Outcomes of the program	7
1.10 Report Structure	8
Chapters 2 and 3 AERP <i>Vet</i>	8
Chapters 4 and 5 AERP <i>Ag</i>	8
1.11 For further information	9
2 VETERINARY - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (ANIMAL)	10
2.1 Adverse experience report summaries for each species listed by active constituent	10
Active constituent name	10
The species	10
Number of reports	10
Presenting signs	10
Summary of corrective action	10
2.2 Veterinary – standard AERs	11
ABAMECTIN	11
ACEPROMAZINE MALEATE	11
ALBENDAZOLE	12
ALPHA AMYLASE	12
ALPHA-CYPERMETHRIN	12
ALPHAXALONE	13
ALUMINIUM HYDROXIDE	14
AMITRAZ	15

AMOXYCILLIN AS AMOXYCILLIN TRIHYDRATE	15
ANAPLASMA CENTRALE	16
BABESIA BIGEMINA	16
BABESIA BOVIS	17
BENAZEPRIL HYDROCHLORIDE	17
BENZATHINE PENICILLIN	18
BETA GLUCANASE	18
BETAMETHASONE	18
BORDETELLA BRONCHISEPTICA	19
BORDETELLA BRONCHISEPTICA (INACTIVATED CELL FREE EXTRACT)	20
BORDETELLA BRONCHISEPTICA KILLED VACCINE	22
BORIC ACID	22
CALCIUM PENTOSAN POLYSULFATE	23
CAMPYLOBACTER FELIS (VIBRO FETUS) VENEREALIS BIOTYPE 1	23
CaNINE ADENOVIRUS TYPE 2	23
CANINE ADENO VIRUS TYPE 2 – live (infectious hepatitis)	26
CANINE ADENOVIRUS TYPE 2 LIVE (CAV II)	26
CANINE ADENOVIRUS TYPE 2 STRAIN MANHATTAN - LIVE	27
CANINE DISTEMPER	28
CANINE DISTEMPER VIRUS	28
CANINE DISTEMPER VIRUS - LIVING	29
CANINE DISTEMPER VIRUS STRAIN ONDERSTEEPOORT	31
CANINE PARAINFLUENZA	32
CANINE PARAINFLUENZA TYPE 2	33
CANINE PARAINFLUENZA VIRUS	34
CANINE PARAINFLUENZA VIRUS - INACTIVATED	36
CANINE PARVO VIRUS	37
CANINE PARVO VIRUS TYPE 2	38
CANINE PARVOVIRUS - LIVE	39
CANINE PARVO VIRUS STRAIN 154 - live	40
CARBARYL	41
CARPROFEN	42
CEFTIOFUR AS CEFTIOFUR HYDROCHLORIDE	42
CEFUROXIME SODIUM	43
CELLULASE	43
CEPHALEXIN AS CEPHALEXIN MONOHYDRATE	43
CHLAMYDOPHILIA FELIS BAKER STRAIN - LIVE, ATTENUATED	44
CHLORAMPHENICOL	44
CHLORFENVINPHOS	45
CHLORHEXIDINE GLUCONATE	45
CHLORPHENIRAMINE MALEATE	45
CHLORPYRIFOS	46
CLAVULANIC ACID as potassium clavulanate	46
CLOMIPRAMINE HYDROCHLORIDE	47
CLOSTRIDIUM BOTULINUM TYPE C TOXOID	47
CLOSTRIDIUM BOTULINUM TYPE D TOXOID	47

CLOSTRIDIUM CHAUVOEI - FORMOL CULTURE	48
CLOSTRIDIUM CHAUVOEI - killed	48
CLOSTRIDIUM CHAUVOEI - killed	48
CLOSTRIDIUM CHAUVOEI - killed	49
CLOSTRIDIUM CHAUVOEI - Toxoid	49
CLOSTRIDIUM NOVYI TYPE B – Killed	50
CLOSTRIDIUM NOVYI TYPE B - TOXOID	51
CLOSTRIDIUM perfringens type d TOXOID	52
CLOSTRIDIUM SEPTICUM - TOXOID	53
CLOSTRIDIUM TETANI - ANTITOXIN	54
CLOSTRIDIUM TETANI - TOXOID	55
CLOSTRIDIUM TETANI uf TOXOID	56
CLOTTRIMISOLE	56
CObalt edta	57
COpper sulfate	57
COrona virus	57
Cyclosporin	58
Cypermethrin	59
Deltamethrin	59
Deoxycortone pivalate	60
DERACOXIB	60
DESLORELIN AS DESLORELIN ACETATE	60
DEXTROMETHORPHAN HYDROBROMIDE	61
DIAZINON	61
DICYCLANIL	62
DIFLUBENZURON	62
Dihydroseptomycin as the sulfate	63
Doxycycline as doxycycline monohydrate	63
eimeria acervulina oocysts	63
eimeria maxima oocysts	63
eimeria necatrix oocysts	64
eimeria tenella oocysts	64
EMODEPSIDE	64
ENROFLOXACIN	65
EPHEDRINE HYDROCHLORIDE	65
EPrinomectin	66
FEBANTEL	66
FELINE CALICIVIRUS - INACTIVATED	67
FELINE LEUKAEMIA VIRUS – INACTIVATED	68
FELINE PANLEUCOPENIA VIRUS - INACTIVATED	68
FELINE RHINOTRACHEITIS VIRUS - INACTIVATED	70
FENThion	71
FIPRONIL	72
FIROCOXIB	72
Fluazuron	73
FLUMETHRIN	73

Formalin	73
Fungal Protease	74
Gentamycin	74
HEPATITIS CANINE = CANINE ADENOVIRUS	74
Hyoscine as hyoscine methobromide	75
IMIDACLOPRID	75
INACTIVATED salmonella dublin & typhimurium antigens	79
Infectious laryngotracheitis virus strain s.a.2	79
Insulin	80
IVERMECTIN	80
LEPTOSPIRA BORGPETERSENII SEROVAR HARDJO	82
LEPTOSPIRA INTERROGANS SEROVAR POMONA	82
LEPTOSPIROSIS - DOG - LEPTOSPIRA ICTEROHAEMORRHAGIAE	82
LEVAMISOLE hydrochloride	83
Lincomycin as lincomycin hydrochloride	83
LUFENURON	84
M.hypopneumonia – inactivated whole cell culture	85
Melaleuca oil	85
MELOXICAM	85
METHOpene	87
MICONAZOLE NITRATE	87
MILBEMYCIN OXIME	88
MORAxella bovis	89
MOXIDECTIN	90
MYCOpasma hyopneumoniae – inactivated antigen	93
MYO-INOSITOL-HEXAPHOSPHATE PHOSPHOHYDROLASE	94
Nlgergoline freeze dried	94
NICLOSAMIDE	94
NICLOSAMIDE monohydrate - micronised	95
NITENPYRAM	95
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE	96
oatmeal extract	97
OESTRADIOL 17-BETA	97
OXANTEL EMBONATE	97
OXFENDAZOLE	98
OXytetracycline hydrochloride	98
PARVOVIRUS - LIVE	98
PEctinase	99
PENTOBARBITONE SODIUM	99
PERMETHRIN	100
PERMETHRIN (25:75: :CIS:TRANS)	101
PERMETHRIN (40:60: :CIS:TRANS)	101
PIMOBENDAN	104
PIPERONYL BUTOXIDE	105
POLYMYXIN B SULFATE	106
PRAZIQUANTEL	106

PROCAINE PENICILLIN	109
PROPOFOL	110
PYRANTEL as pyrantel embonate	111
PYRETHRINS	112
PYRIPROXYFEN	113
(S)-METHOPRENE	114
SELAMECTIN	114
SELENIUM as sodium selenate	115
Silver sulfadiazine	116
SODIUM PENTOSAN POLYSULFATE	117
Spectinomycin as spectinomycin sulfate	117
SPINOSAD	118
SULFAdiazine	118
SULFadimidine	119
Triclabendazole	119
Triflumuron	119
Trimethoprim	120
Vitamin a	120
Vitamin B1 – thiamine hydrochloride	120
Vitamin D3	121
Vitamin E	121
Xylanase	121
zeta-cypermethrin	122
zinc edta	122

3	VETERINARY - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (HUMAN)	123
3.1	Adverse experience report summaries involving humans listed by active constituent	123
	Active constituent name	123
	Number of reports	123
	Presenting signs	123
	3.2 Veterinary – Human AERs	124
	Chlorfenvinphos	124
	CLOSTRIDIUM CHAUVOEI - Toxoid	124
	CLOSTRIDIUM CHAUVOEI TOXIOD AND INACTIVATED CELLS	124
	CLOSTRIDIUM NOVYI TYPE B TOXIOD AND INACTIVATED Cells	125
	CLOSTRIDIUM perfringens type d TOXOID	125
	CLOSTRIDIUM septicum - TOXOID	125
	CLOSTRIDIUM TETANI - TOXOID	126
	Colloidal oatmeal	126
	CORYNEBACTERIUM PSEUDOTUBERCULOSIS TOXOID and inactivate	126
	Cypermethrin	127
	FIPRONIL	127
	IMIDACLOPRID	127
	MOXIDECTIN	128
	MYCOBACTERIUM PARATUBERCULOSIS	128
	N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE	129

PERMETHRIN (40:60: :CIS:TRANS)	129
PIPERONYL BUTOXIDE	129
Pyrethrins	130
(S)-METHOPRENE	130
SELAMECTIN	130
<hr/>	
4 AGRICULTURE - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (STANDARD)	131
4.1 Adverse experience report summaries involving crop damage, domestic animal harm, environmental damage or lack of efficacy listed by active constituent	131
Active constituent name	131
Number of reports	131
Presenting signs	131
4.2 Agriculture Chemical – Standard AERs	132
BACILLUS THURINGIENSIS SUBSP KURSTAKI DELTA ENDOTOXINS A	132
buprofezin	132
DIURON	132
indoxacarb (25:75)	133
MCPA PRESENT AS THE POTASSIUM SALT	133
TERBUTRYN	133
<hr/>	
5 AGRICULTURE - SUMMARY OF ADVERSE EXPERIENCE REPORTS 2008 (HUMAN)	134
5.1 Adverse experience report summaries involving humans listed by active constituent	134
Active constituent name	134
Number of reports	134
Presenting signs	134
5.2 Agriculture Chemical – Human AERs	135
BIFENTHRIN	135
GLYPHOSATE PRESENT AS THE POTASSIUM SALT	135
<hr/>	
GLOSSARY	137
LIST OF ACTIVE CONSTITUENTS	139